The article discusses the limitations of autologous CAR T cell therapies, notably their cost and manufacturing challenges, which hinder patient access. It explores the potential of allogeneic CAR T cells that improve treatment accessibility but are prone to immune rejection. The authors propose a novel strategy utilizing lymphotropic viruses' immune evasion properties, particularly HIV-1 Nef, that can protect CAR T cells from host immune attacks and enhance their in vivo survival. Although promising, the findings indicate that additional mechanisms are necessary for sustaining effective allogeneic CAR T cell therapy.
Allogeneic CAR T cell therapies, despite their promise for wider access and improved outcomes, face challenges of immune rejection that must be effectively mitigated.
The strategy of using viral evasins demonstrates potential by lowering HLA class I expression, thus protecting CAR T cells from CD8+ T cell rejection.
Collection
[
|
...
]